Changzhou Qianhong BiopharmaLTD Past Earnings Performance
Past criteria checks 2/6
Changzhou Qianhong BiopharmaLTD has been growing earnings at an average annual rate of 6.4%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 10.1% per year. Changzhou Qianhong BiopharmaLTD's return on equity is 7.2%, and it has net margins of 10%.
Key information
6.4%
Earnings growth rate
6.4%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 10.1% |
Return on equity | 7.2% |
Net Margin | 10.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Changzhou Qianhong BiopharmaLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,814 | 182 | 526 | 97 |
30 Sep 23 | 2,121 | 253 | 510 | 94 |
30 Jun 23 | 2,223 | 241 | 559 | 99 |
31 Mar 23 | 2,360 | 281 | 552 | 98 |
31 Dec 22 | 2,304 | 323 | 556 | 88 |
30 Sep 22 | 2,155 | 260 | 663 | 75 |
30 Jun 22 | 2,139 | 294 | 609 | 74 |
31 Mar 22 | 2,036 | 255 | 598 | 71 |
01 Jan 22 | 1,875 | 181 | 588 | 71 |
30 Sep 21 | 1,873 | -88 | 515 | 70 |
30 Jun 21 | 1,886 | -107 | 546 | 69 |
31 Mar 21 | 1,913 | -52 | 509 | 68 |
31 Dec 20 | 1,668 | -132 | 488 | 69 |
30 Sep 20 | 1,694 | 188 | 486 | 55 |
30 Jun 20 | 1,487 | 151 | 487 | 61 |
31 Mar 20 | 1,454 | 148 | 488 | 64 |
31 Dec 19 | 1,675 | 263 | 476 | 65 |
30 Sep 19 | 1,462 | 232 | 492 | 67 |
30 Jun 19 | 1,490 | 233 | 468 | 67 |
31 Mar 19 | 1,350 | 227 | 452 | 66 |
31 Dec 18 | 1,322 | 221 | 436 | 67 |
30 Sep 18 | 1,312 | 222 | 413 | 68 |
30 Jun 18 | 1,223 | 202 | 361 | 96 |
31 Mar 18 | 1,160 | 197 | 400 | 16 |
31 Dec 17 | 1,065 | 183 | 345 | 64 |
30 Sep 17 | 995 | 212 | 324 | 49 |
30 Jun 17 | 931 | 226 | 356 | 0 |
31 Mar 17 | 863 | 225 | 346 | 0 |
31 Dec 16 | 776 | 224 | 333 | 0 |
30 Sep 16 | 773 | 250 | 324 | 0 |
30 Jun 16 | 788 | 277 | 306 | 0 |
31 Mar 16 | 750 | 277 | 295 | 0 |
31 Dec 15 | 757 | 267 | 297 | 0 |
30 Sep 15 | 730 | 268 | 270 | 0 |
30 Jun 15 | 744 | 270 | 265 | 0 |
31 Mar 15 | 771 | 259 | 274 | 0 |
31 Dec 14 | 815 | 245 | 280 | 0 |
30 Sep 14 | 807 | 226 | 244 | 0 |
30 Jun 14 | 791 | 205 | 221 | 0 |
31 Mar 14 | 832 | 191 | 217 | 0 |
31 Dec 13 | 861 | 187 | 210 | 0 |
30 Sep 13 | 907 | 188 | 211 | 0 |
30 Jun 13 | 847 | 178 | 204 | 0 |
Quality Earnings: 002550 has high quality earnings.
Growing Profit Margin: 002550's current net profit margins (10%) are lower than last year (14%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002550's earnings have grown by 6.4% per year over the past 5 years.
Accelerating Growth: 002550's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002550 had negative earnings growth (-43.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.5%).
Return on Equity
High ROE: 002550's Return on Equity (7.2%) is considered low.